Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pharmacists To Get New Substitution Powers To Tackle Brexit Shortage Risk

Executive Summary

In an effort to address possible serious drug shortages in the event of a no-deal Brexit, the UK government has formally proposed giving pharmacists wide powers to dispense alternative medicines such as different forms, generics, biosimilars, or “therapeutically equivalent” drugs.

You may also be interested in...



‘No-Deal Brexit’ Pharmacy Substitution Rules Take Effect In UK

UK pharmacists can now dispense a different medicine from the one prescribed, even if it contains a different active ingredient, under new laws on “serious shortage protocols” that came into force on 1 July as part of the government’s “no-deal Brexit” preparations.

How The UK Regulatory System Would Work In A No-Deal Brexit – Part 1

Regulations that would allow the UK MHRA to work as a standalone regulator in the event of a no-deal Brexit have been laid before parliament. They cover a host of areas including new drug approval procedures, conversion of existing EU marketing authorizations into UK ones, pediatric and orphan exclusivities, imported medicines, and regulatory fees.

UK Committee Urges Clarity On No-Deal Brexit Medicine Supplies

A parliamentary committee has called on the health department to provide more clarity as to how it plans to ensure continuity of medicine supplies in the event of a no-deal Brexit. At the same time, the government has produced a set of draft regulations allowing the UK MHRA to take over drug regulatory functions currently performed at EU level.

Related Content

Topics

UsernamePublicRestriction

Register

PS124603

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel